MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Purchases Shares of 3,624 Avantor, Inc. (NYSE:AVTR)

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH acquired a new position in shares of Avantor, Inc. (NYSE:AVTR) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,624 shares of the company’s stock, valued at approximately $93,000.

Several other institutional investors also recently modified their holdings of AVTR. Mesirow Institutional Investment Management Inc. purchased a new position in shares of Avantor during the 4th quarter valued at about $2,842,000. Raymond James & Associates boosted its stake in shares of Avantor by 84.8% in the 4th quarter. Raymond James & Associates now owns 1,165,646 shares of the company’s stock valued at $26,612,000 after purchasing an additional 534,901 shares in the last quarter. Federated Hermes Inc. grew its holdings in shares of Avantor by 19.9% during the 4th quarter. Federated Hermes Inc. now owns 628,189 shares of the company’s stock valued at $14,342,000 after purchasing an additional 104,296 shares during the last quarter. BNP Paribas Financial Markets raised its position in Avantor by 146.1% in the 4th quarter. BNP Paribas Financial Markets now owns 217,296 shares of the company’s stock worth $4,961,000 after purchasing an additional 129,010 shares during the period. Finally, DAVENPORT & Co LLC lifted its stake in Avantor by 17.6% in the fourth quarter. DAVENPORT & Co LLC now owns 2,283,767 shares of the company’s stock worth $52,430,000 after purchasing an additional 342,452 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Avantor from $23.00 to $25.00 and gave the stock a “hold” rating in a research note on Thursday, April 18th. Robert W. Baird lowered their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, April 29th. Evercore ISI cut their target price on Avantor from $28.00 to $27.00 and set an “outperform” rating on the stock in a research note on Tuesday. Finally, Barclays reduced their price target on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, June 28th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $26.29.

Avantor Trading Down 0.9 %

Avantor stock opened at $20.58 on Wednesday. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.94. Avantor, Inc. has a 12-month low of $16.63 and a 12-month high of $26.16. The firm has a market capitalization of $13.98 billion, a price-to-earnings ratio of 52.77, a P/E/G ratio of 2.15 and a beta of 1.32. The firm has a 50 day moving average of $23.66 and a 200 day moving average of $23.81.

Avantor (NYSE:AVTR) last issued its quarterly earnings results on Friday, April 26th. The company reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.02. Avantor had a return on equity of 13.01% and a net margin of 3.79%. The business had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.68 billion. During the same quarter in the prior year, the business posted $0.29 EPS. Avantor’s revenue for the quarter was down 5.6% compared to the same quarter last year. As a group, research analysts predict that Avantor, Inc. will post 1.01 earnings per share for the current year.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.